On November 25, 2004, the State Food and Drug Administration (SFDA) approved the phase I clinical trial of compound AIDS vaccine developed by Changchun Baike Pharmaceutical Company Limited. This is the first time China conduct such tests.

Since 1996 Chinese researchers have been studying the AIDS virus genes that are prevalent in China, including the envelope protein and core protein of the virus. The tested vaccine consists of DNA vaccine and recombinant virus vector vaccine. DNA vaccine will be first inoculated and then recombinant virus vector vaccine, immunity against AIDS will then be developed. Vaccine itself will not cause infection. Inoculated monkeys found no abnormal reactions after being attacked by AIDS viruses.

SFDA has established an accelerating procedure for new drugs with preventive and therapeutic efficacy in the treatment of complicated and severe disease (such as AIDS, SARS, etc.), the standards do not lower and the procedures are complete. SFDA will continue to promote the research of such drugs in the future.